Cellceutix’ CEO George Evans said: "This is a big step for Cellceutix and represents our last hurdle before asking the US ['Food and Drug Administration] FDA for permission to conduct Phase 1 human studies." Kevetrin is intended to treat cancers that have developed resistance to available treatments, including both lung and breast cancer.
Full Article at OutsourcingPharma